Cover Image
市場調查報告書

生長激素藥的全球市場 (∼2027年):生長激素系&Mecasermin系首發藥及生物相似藥 (Norditropin、Genotropin、Humatrope、Saizen、Nutropin、Omnitrope、Zomacton)、R&D、主要企業分析

Global Growth Hormone Drugs Market Forecast to 2027: Somatropin and Mecasermin Based Drugs, Innovator Generics and Biosimilars, Norditropin, Genotropin, Humatrope, Saizen, Nutropin, Omnitrope, Zomacton, R&D and Leading Companies

出版商 Visiongain Ltd 商品編碼 599413
出版日期 內容資訊 英文 184 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生長激素藥的全球市場 (∼2027年):生長激素系&Mecasermin系首發藥及生物相似藥 (Norditropin、Genotropin、Humatrope、Saizen、Nutropin、Omnitrope、Zomacton)、R&D、主要企業分析 Global Growth Hormone Drugs Market Forecast to 2027: Somatropin and Mecasermin Based Drugs, Innovator Generics and Biosimilars, Norditropin, Genotropin, Humatrope, Saizen, Nutropin, Omnitrope, Zomacton, R&D and Leading Companies
出版日期: 2017年11月29日 內容資訊: 英文 184 Pages
簡介

2016年的全球生長激素藥的市場估計達到38億美元的規模。預計從2017年到2027年以3.6%的年複合成長率成長。

本報告提供全球生長激素藥的市場調查,市場定義和概要,生長激素缺乏症 (GHD)的概要與罹患情形,生長激素藥的市場規模的變化與預測,市場成長的影響因素分析,主要的生長激素藥的簡介及銷售情況與預測,R&D狀況等彙整資料。

第1章 報告概要

第2章 關於生長激素缺乏症 (GHD)

  • 關於生長激素
  • 所謂GHD
  • GHD的診斷
  • GHD的治療

第3章 流行病學

  • 美國
  • EU
    • 丹麥
    • 英國
    • 法國
    • 比利時
    • 西班牙
    • 俄羅斯
  • 日本

第4章 簡介:全球生長激素藥市場

  • 市場結構
  • 市場定義、範圍
  • 分類
    • 創新者生物製劑 (首發品)
    • 生物相似藥

第5章 全球市場的變化與預測

  • 目前市場規模
  • 收益規模的變化
  • 市場預測
  • 市場變化與預測:各首發品、生物相似藥
  • 市場變化與預測:各分子
    • 收益的變化與預測、市場佔有率
      • 生長激素系
      • Mecasermin系
  • 市場成長的促進因素&抑制因素、各種趨勢

第6章 主要生長激素藥

  • 主要藥物的銷售情況與預測
  • 首發品
    • Norditropin:Novo Nordisk
    • Genotropin:Pfizer
    • Humatrope:Eli Lilly
    • Saizen:Merck KGaA
    • Nutropin, Nutropin AQ:Roche/Ipsen
  • 生物相似藥
    • Omnitrope:Novartis
    • Zomactan / Tev-tropin / Growject:Ferring / JCR Pharmaceuticals

第7章 主要國家市場預測

  • 各地區、國家佔有率
  • 銷售情況與預測
  • 美國
  • 歐盟5國
    • 英國
    • 西班牙
    • 義大利
    • 德國
    • 法國
  • 日本

第8章 GHD治療藥的R&D

  • 開發平台中的活性分子
  • 開發平台藥物的新的作用機制
  • 臨床階段的開發平台分子:概要
    • 申請中
      • Macrilen (Macimorelin acetate, AEZS-130, EP 1572):Aeterna Zentaris
    • 第三階段
      • VRS-317 (Somavaratan):Versartis
      • ACP-001 (TransCon Growth Hormone):Ascendis Pharma
      • MOD-4023 (Somatrogon, Lagova, PF-06836922):OPKO Health
      • NN-8640 (Somapacitan, NNC0195-0092):Novo Nordisk
    • 第二階段
      • GX-H9 (HL-2356, hGH-hyFc):Genexine
      • HM10560A (Efpegsomatropin, LAPS-Hgh, LAPS-rhGH):Hanmi Pharmaceutical
      • ALT-P1 (CJ-40002, hGH-NexP):Alteogen
    • 第一階段
      • CP-024:Critical Pharmaceuticals
  • 開發中止的開發平台分子

第9章 定性分析

  • SWOT分析

第10章 主要企業

  • 主要企業的銷售情況
  • 主要企業
    • Novo Nordisk
    • Pfizer Inc.
    • Eli Lily and Company
    • Merck & Co., Inc
    • Roche
    • Novartis

第11章 摘要整理、建議

第12章 用語

附錄

目錄
Product Code: PHA0261

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 184-page report you will receive 78 tables and 106 figures- all unavailable elsewhere.

The 184-page report provides clear detailed insight into the Growth Hormone Drugs Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

The Global Growth Hormone Drugs market was estimated at $3.8 billion in 2016 and is expected to grow at a CAGR of 3.6% during 2017-2027. Somatropin based drugs led the market with 98.9% of the market share.

Read on to discover how this definitive report can transform your own research and save you time.

The new market assessment benefits research, analysis and planning in seven main ways:

  • World growth hormone drugs market revenue to 2027 - discover that industry's overall sales potential
  • Two product classes' revenues to 2027 - investigate categories at world level, finding the most lucrative and promising therapy classes
  • Seven leading drugs' revenues to 2027 - find sales predictions for top and emerging products, seeing how agents compete and succeed
  • 7 national markets in the Americas, Europe and Asia covered, with forecasts to 2027 - discover the best countries for trade expansion
  • Activities of established, rising and emerging companies - hear about firms' products, capabilities, advances, collaborations and outlooks
  • R&D for growth hormone medicines - investigate progress in that industry, exploring technological, clinical and commercial opportunities
  • Analysis of what stimulates and restrains that industry and market - assess challenges, strengths, competition and opportunities, helping you succeed.

There you explore business intelligence with research, opinions and predictions found only in that work.

Trying our investigation now lets you discover trends, opportunities and prospects For growth hormone drugs, our report shows you data, trends, opportunities and multilevel sales forecasts. So, avoid missing out. Instead please get that new analysis here now.

Report highlights

184-pages, 78 tables and 106 figures

Growth Hormone Drugs Market Forecast from 2017 to 2027

This report also breaks down the revenue forecast for the main submarkets:

  • Innovator Generics
  • Biosimilars
  • Mecasermin based drugs
  • Somatropin based drugs

Analysis of the Innovator Generics drugs market. Revenue forecasts to 2027 are provided for the following drugs:

  • Norditropin
  • Genotropin
  • Humatrope
  • Saizen
  • Nutropin

Analysis of the Biosimilar drugs market. Revenue forecasts to 2027 are provided for the following drugs:

  • Omnitrope
  • Zomactan. Tev-tropin/ Growject

Analysis of key players in Growth Hormone Drugs

  • Merck KGaA
  • Roche
  • Novartis
  • Novo Nordisk
  • Eli Lilly and Co.
  • Pfizer Inc.

Regional Growth Hormone Drugs market forecasts from 2017-2027

  • US forecast 2017-2027,
  • Japan forecast 2017-2027
  • Germany forecast 2017-2027
  • UK forecast 2017-2027
  • France forecast 2017-2027
  • Italy forecast 2017-2027
  • Spain forecast 2017-2027

image1

Key questions answered

  • How is the Growth Hormone Drugs market evolving?
  • What is driving and restraining Growth Hormone Drugs market dynamics?
  • How will each Growth Hormone Drugs submarket market grow over the forecast period and how much Sales will these submarkets account for in 2026?
  • How will market shares of each Growth Hormone Drugs submarket develop from 2017-2027?
  • Which individual technologies will prevail and how will these shifts be responded to?
  • Which Growth Hormone Drugs submarket will be the main driver of the overall market from 2017-2027?
  • How will political and regulatory factors influence regional Growth Hormone Drugs markets and submarkets?
  • Will leading national Growth Hormone Drugs markets broadly follow macroeconomic dynamics, or will individual country sectors outperform the rest of the economy?
  • How will market shares of the national markets change by 2026 and which nation will lead the market in 2026?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the sector evolve as alliances form during the period between 2017 and 2027?

Target audience

  • Leading Growth Hormone Drug Compaies
  • Suppliers
  • Contractors
  • Technologists
  • R&D staff
  • Consultants
  • Analysts
  • CEO's
  • CIO's
  • COO's
  • Business development managers
  • Investors
  • Governments
  • Agencies
  • Industry organisations
  • Banks

With our study you see how that market can develop and perform, benefiting your reputation for insight and authority.

Table of Contents

1. Report Overview

  • 1.1 Global Growth Hormone Drugs Market Overview
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report Include:
  • 1.5 Who is This Report For?
  • 1.6 Methodology
    • 1.6.1 Primary Research
    • 1.6.2 Secondary Research
    • 1.6.3 Market Evaluation & Forecasting Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated visiongain Reports
  • 1.9 About visiongain

2. Introduction to Growth Hormone Deficiency (GHD)

  • 2.1 What is Growth Hormone?
  • 2.2 What is GHD?
  • 2.3 Diagnosis of GHD
  • 2.4 Treatment of GHD

3. Epidemiology

  • 3.1 US
  • 3.2 EU
    • 3.2.1 Denmark
    • 3.2.2 UK
    • 3.2.3 France
    • 3.2.4 Belgium
    • 3.2.5 Spain
  • 3.3 Russia
  • 3.4 Japan

4. Introduction to the Global Growth Hormone Drugs Market

  • 4.1 Market Structure
  • 4.2 Market Definition and Scope
  • 4.3 Classification by Innovator Biologics or Biosimilars
    • 4.3.1 Innovator Biologics
    • 4.3.2 Biosimilars

5. Global Growth Hormone Drugs Market 2017-2027

  • 5.1 Global Growth Hormone Drugs Market 2016
  • 5.2 Global Growth Hormone Market Historical Revenue, 2011-2016
  • 5.3 Global Growth Hormone Drugs Market Forecast 2017-2027
  • 5.4 Market Segmentation by Innovator Biologics and Biosimilars
    • 5.4.1 Global Growth Hormone: Innovator Biologics and Biosimilar Drugs Market Forecast 2017-2027
      • 5.4.1.1 Innovator Drugs Market Forecast 2016-2027
      • 5.4.1.2 Biosimilar Drugs Market Forecast 2016-2027
    • 5.4.2 Innovator and Biosimilar Drugs Market Share Forecast 2017-2027
  • 5.5 Market Segmentation by Molecule
    • 5.5.1 Global Growth Hormone Drugs Historical Revenue 2011-2016
    • 5.5.2 Global Growth Hormone Drugs Forecast 2017-2027
      • 5.5.2.1 Somatropin Based Growth Hormone Drugs Market Forecast 2016-2027
      • 5.5.2.2 Mecasermin Based Growth Hormone Drugs Market Forecast 2016-2027
    • 5.5.3 Mecasermin and Somatropin Based Drugs Market Share Forecast 2017-2027
  • 5.6 Global Growth Hormone Drugs Market Drivers, Restraints and Trends

6. Leading Growth Hormone Drugs

  • 6.1 Snapshot of Growth Hormone Drugs' 2016 Sales, Historical Sales, & Forecast 2017-2027
  • 6.2 Innovator Drugs
    • 6.2.1 Norditropin - Novo Nordisk
      • 6.2.1.1 Drug Profile
      • 6.2.1.2 Norditropin Historical Sales 2011-2016
      • 6.2.1.3 Norditropin Revenue Forecast 2017-2027
      • 6.2.1.4 Norditropin Sales by Geography, 2016
    • 6.2.2 Genotropin - Pfizer
      • 6.2.2.1 Drug Profile
      • 6.2.2.2 Genotropin Historical Sales 2011-2016
      • 6.2.2.3 Genotropin Revenue Forecast 2017-2027
      • 6.2.2.4 Genotropin Sales by Geography, 2016
    • 6.2.3 Humatrope - Eli Lilly
      • 6.2.3.1 Drug Profile
      • 6.2.3.2 Humatrope Historical Sales 2011-2016
      • 6.2.3.3 Humatrope Revenue Forecast 2017-2027
      • 6.2.3.4 Humatrope Sales by Geography, 2016
    • 6.2.4 Saizen - Merck KGaA
      • 6.2.4.1 Drug Profile
      • 6.2.4.2 Saizen Historical Sales 2011-2016
      • 6.2.4.3 Saizen Revenue Forecast 2017-2027
      • 6.2.4.4 Saizen Sales by Geography, 2016
    • 6.2.5 Nutropin, Nutropin AQ - Roche/Ipsen
      • 6.2.5.1 Drug Profile
      • 6.2.5.2 Nutropin, Nutropin AQ Historical Sales
      • 6.2.5.3 Nutropin, Nutropin AQ Revenue Forecast 2017-2027
      • 6.2.5.4 Nutropin, Nutropin AQ Sales by Geography, 2016
  • 6.3 Biosimilars
    • 6.3.1 Omnitrope - Novartis
      • 6.3.1.1 Drug Profile
      • 6.3.1.2 Omnitrope Historical Sales
      • 6.3.1.3 Omnitrope Revenue Forecast 2017-2027
      • 6.3.1.4 Omnitrope Sales by Geography, 2016
    • 6.3.2 Zomactan / Tev-tropin / Growject - Ferring / JCR Pharmaceuticals
    • 6.3.2.1 Drug Profile:

7. Leading National Markets Forecast 2017-2027

  • 7.1 Geographical Breakdown of Global Growth Hormone Drugs Market, 2016
    • 7.1.1 Region-wise Breakdown of Global Growth Hormone Drugs Market, 2016
    • 7.1.2 Country-wise Breakdown of Global Growth Hormone Drugs Market, 2016
  • 7.2 Region-wise Historical Sales of Global Growth Hormone Drugs Market, 2011-2016
  • 7.3 Region-wise Forecast of Global Growth Hormone Drugs Market, 2017-2027
  • 7.4 US Growth Hormone Drugs Market, 2016
    • 7.4.1 US Growth Hormone Drugs Historical Sales, 2011-2016
    • 7.4.2 US Growth Hormone Revenue Forecast, 2017-2027
  • 7.5 EU5 Growth Hormone Drugs Market, 2016
    • 7.5.1 EU5 Growth Hormone Historical Sales 2011-2016
    • 7.5.2 EU5 Growth Hormone Revenue Forecast, 2017-2027
    • 7.5.2.1 UK Growth Hormone Revenue Forecast, 2017-2027
    • 7.5.2.2 Spain Growth Hormone Revenue Forecast, 2017-2027
    • 7.5.2.3 Italy Growth Hormone Revenue Forecast 2017-2027
    • 7.5.2.4 Germany Growth Hormone Revenue Forecast 2017-2027
    • 7.5.2.5 France Growth Hormone Revenue Forecast, 2017-2027
  • 7.6 Japan Growth Hormone Drugs Market, 2016
    • 7.6.1 Japan Growth Hormone Drugs Historical sales, 2011-2016
    • 7.6.2 Japan Growth Hormone Revenue Forecast, 2017-2027

8. Research and Development for Treating GHD

  • 8.1 Active Pipeline Molecules
  • 8.2 Novel Mechanism of Action of Pipeline Drugs
  • 8.3 Clinical-stage Pipeline Molecules: Brief Overview
    • 8.3.1 Pipeline Drugs in Registration
      • 8.3.1.1 Macrilen (Macimorelin acetate, AEZS-130, EP 1572) - Aeterna Zentaris
    • 8.3.2 Pipeline Drugs in Phase III
      • 8.3.2.1 VRS-317 (Somavaratan) - Versartis
      • 8.3.2.2 ACP-001 (TransCon Growth Hormone) - Ascendis Pharma
      • 8.3.2.3 MOD-4023 (Somatrogon, Lagova, PF-06836922) - OPKO Health
      • 8.3.2.4 NN-8640 (Somapacitan, NNC0195-0092) - Novo Nordisk
    • 8.3.3 Pipeline Drugs in Phase II
      • 8.3.3.1 GX-H9 (HL-2356, hGH-hyFc) - Genexine
      • 8.3.3.2 HM10560A (Efpegsomatropin, LAPS-Hgh, LAPS-rhGH) - Hanmi Pharmaceutical
      • 8.3.3.3 ALT-P1 (CJ-40002, hGH-NexP) - Alteogen
    • 8.3.4 Pipeline Drugs in Phase I
      • 8.3.4.1 CP-024 - Critical Pharmaceuticals
  • 8.4 Discontinued Pipeline Molecules

9. Qualitative Analysis of the Global Growth Hormone Drugs Market

  • 9.1 SWOT Analysis, 2016

10. Leading Companies in Global Growth Hormone Drugs Market, 2016

  • 10.1 Growth Hormone Drugs Market Players Historical Sales
  • 10.2 Key Players
    • 10.2.1 Novo Nordisk
      • 10.2.1.1 SWOT Analysis
    • 10.2.2 Pfizer Inc.
      • 10.2.2.1 SWOT Analysis
    • 10.2.3 Eli Lily and Company
      • 10.2.3.1 SWOT Analysis
    • 10.2.4 Merck & Co., Inc
      • 10.2.4.1 SWOT Analysis
    • 10.2.5 Roche
      • 10.2.5.1 SWOT Analysis
    • 10.2.6 Novartis
      • 10.2.6.1 SWOT Analysis

11. Executive Summary and Recommendations

12. Glossary

  • Associated visiongain Reports

Appendix A

  • About visiongain

Appendix B

Table of Tables

  • Table 1.1 Example of Growth Hormone Drugs Market by Regional Market Forecast 2017-2027 ($m, AGR %)
  • Table 3.1 Incidence Rate of GHD based on Age of Onset, Denmark
  • Table 3.2 Incidence & Prevalence of GHD Cases in Individuals Aged 0 to 20 years, by Diagnosis, in Cataluña, Spain
  • Table 3.3 Incidence & Prevalence of GHD Cases, Russia
  • Table 4.1 List of Innovator Biologics for the treatment of GHD
  • Table 5.1 Global Growth Hormone Drugs Market by Markets: Revenue ($m), and Market Share (%), 2016
  • Table 5.2 Global Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.3 Comparative Overview of Key Growth Hormone Devices
  • Table 5.4 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.5 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: AGR (%)
  • Table 5.6 Global Growth Hormone Innovator Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.7 Global Growth Hormone Biosimilar Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.8 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: Market Share (%)
  • Table 5.9 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Historical Revenue ($m), AGR (%), CAGR (%)
  • Table 5.10 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.11 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: AGR (%)
  • Table 5.12 Global Somatropin Based Growth Hormone Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.13 Global Mecasermin Based Growth Hormone Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.14 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Market Share (%)
  • Table 6.1 Leading Growth Hormone Drug Sales, Revenue($m), Market Share (%), 2016
  • Table 6.2 Norditropin: Drug Profile
  • Table 6.3 Norditropin Global Historical Sales: Revenue ($million), 2011-2016
  • Table 6.4 Norditropin Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.5 Patent Expiry of Norditropin
  • Table 6.6 Genotropin: Drug Profile
  • Table 6.7 Genotropin Global Historical Sales: Revenue ($million), AGR (%), CAGR (%) 2011-2016
  • Table 6.8 Genotropin Sales Forecast 2016-2027: Revenue ($million), AGR (%), CAGR (%)
  • Table 6.9 Humatrope: Drug Profile
  • Table 6.10 Humatrope Global Historical Sales: Revenue ($m), AGR (%), CAGR (%) 2011-2016
  • Table 6.11 Humatrope Sales Forecast 2016-2027: Revenue ($million), AGR (%), CAGR (%)
  • Table 6.12 Saizen: Drug Profile
  • Table 6.13 Saizen Global Historical Sales: Revenue ($million), AGR (%), CAGR (%) 2011-2016
  • Table 6.14 Saizen Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.15 Nutropin AQ: Drug Profile
  • Table 6.16 Nutropin and Nutropin AQ Combined Global Sales: Revenue ($million), 2011-2016
  • Table 6.17 Nutropin and Nutropin AQ Combined Sales Forecast 2016-2027: Revenue ($million), AGR (%), CAGR (%)
  • Table 6.18 Omnitrope: Drug Profile
  • Table 6.19 Omnitrope Global Sales: Revenue ($million), AGR (%), CAGR (%) 2011-2016
  • Table 6.20 Omnitrope Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.21 Zomacton: Drug Profile
  • Table 7.1 Global Growth Hormone Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
  • Table 7.2 Global Growth Hormone Drugs Market by Country: Revenue ($m), and Market Share (%), 2016
  • Table 7.3 Global Growth Hormone Drugs Market Historical Sales: Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 7.4 Global Growth Hormone Drugs Market by Region: AGR (%) 2012-2016
  • Table 7.5 Global Growth Hormone Drugs Market by Region: Historical Market Share 2011-2016 (%)
  • Table 7.6 Global Growth Hormone Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 7.7 Global Growth Hormone Drugs Market by Region: AGR (%) 2016-2027
  • Table 7.8 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2017-2027 (%)
  • Table 7.9 List of Growth Hormone Drugs Approved in the US, 2017
  • Table 7.10 US Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%), CAGR (%)
  • Table 7.11 US Patent and Exclusivity Status of Growth Hormone Drugs Approved, 2017
  • Table 7.12 US Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 7.13 EU5 Growth Hormone Drugs Market 2016: Global Market Share (%)
  • Table 7.14 EU5 Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%), CAGR (%)
  • Table 7.15 EU5 Growth Hormone Drugs Market by Region: Historical Market Share Forecast 2011-2016 (%)
  • Table 7.16 EU5 Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 7.17 EU5 Growth Hormone Drugs Market By Region: Market Share Forecast 2017-2027 (%)
  • Table 7.18 EU5 Growth Hormone Drugs Market Forecast by Region: AGR 2016-2027 (%)
  • Table 7.19 Patent and Exclusivity Status of Growth Hormone Drugs Approved in the US, 2017
  • Table 7.20 UK Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 7.21 List of Growth Hormone Drugs Approved in Spain, 2017
  • Table 7.22 Spain Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 7.23 Italy Growth Hormone Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 7.24 Germany Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 7.25 List of Growth Hormone Drugs Approved in France, 2017
  • Table 7.26 France Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 7.27 Japan Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%), CAGR (%)
  • Table 7.28 Japan Growth Hormone Drugs Market Forecast Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 8.1: Active Pipeline Molecules under Development for Treating GHD
  • Table 8.2 Key Discontinued GHD Pipeline Candidates
  • Table 10.1 Key Drugs in the Global Growth Hormone Drugs Market
  • Table 10.2 Global Growth Hormone Drugs Market Players: Historical Revenue ($m), 2011-2016
  • Table 10.3 Novo Nordisk A/S: Overview
  • Table 10.4 Pfizer: Overview
  • Table 10.5 Eli Lilly and Company: Overview
  • Table 10.6 Merck: Overview 2016
  • Table 10.7 Roche: Overview
  • Table 10.8 Novartis: Overview

Table of Figures

  • Figure 1.1 Global Growth Hormone Drugs Market Segmentation Overview
  • Figure 1.2 Example of Growth Hormone Drugs Market by Regional Market Share Forecast 2017, 2022, 2027 (%)
  • Figure 2.1 Growth Hormone Signaling Pathway
  • Figure 4.1 Global Growth Hormone Drugs Market Segmentation Overview
  • Figure 5.1 Global Growth Hormone Drugs Market, Segmentation by Innovator Drugs and Biosimilars, Market Share 2016 (%)
  • Figure 5.2 Global Growth Hormone Drugs Market Segmentation by Molecule, Market Share 2016 (%)
  • Figure 5.3 Global Growth Hormone Drugs Market Historical Revenue 2011-2016: Revenue ($m), AGR (%)
  • Figure 5.4 Global Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 5.5 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars, Revenue 2016 ($m)
  • Figure 5.6 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars, Market Share 2016 (%)
  • Figure 5.7 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: Revenue ($m), Global AGR (%)
  • Figure 5.8 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
  • Figure 5.9 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: AGR (%)
  • Figure 5.10 Global Growth Hormone Innovator Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 5.11 Global Biosimilar Drugs Market 2016-2027: Revenue ($m), Growth Hormone AGR (%)
  • Figure 5.12 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars 2016-2027: Market Share (%)
  • Figure 5.13 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars, Market Share Forecast 2017 (%)
  • Figure 5.14 Global Growth Hormone Drugs Market Segmentation by Innovator Drugs and Biosimilars: Market Share Forecast 2027 (%)
  • Figure 5.15 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs, Revenue 2016 ($m)
  • Figure 5.16 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based, Market Share 2016 (%)
  • Figure 5.17 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2011-2016: Revenue ($m), Global AGR (%)
  • Figure 5.18 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Revenue ($m), Global AGR (%)
  • Figure 5.19 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
  • Figure 5.20 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Growth Hormone Drugs 2016-2027: AGR (%)
  • Figure 5.21 Global Somatropin Based Growth Hormone Drugs Market 2016-2027: Revenue ($m), AGR (%)
  • Figure 5.22 Global Mecasermin Based Growth Hormone Drugs Market 2016-2027 2016-2027: Revenue ($m), AGR (%)
  • Figure 5.23 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs 2016-2027: Market Share (%)
  • Figure 5.24 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs, Market Share Forecast 2017 (%)
  • Figure 5.25 Global Growth Hormone Drugs Market Segmentation by Somatropin Based and Mecasermin Based Drugs: Market Share Forecast 2027 (%)
  • Figure 5.26 Trends in Global Growth Hormone Drugs Market
  • Figure 5.27 Trends in Global Growth Hormone Drugs Market
  • Figure 6.1 Leading Growth Hormone Drug Sales, Revenue ($m), 2016
  • Figure 6.2 Leading Growth Hormone Drug Sales, Market Share (%), 2016
  • Figure 6.3 Growth Hormone Drugs Sales Forecast, Market Share (%), 2027
  • Figure 6.4 Leading Growth Hormone, Historical Sales, Revenue ($m), 2011-2016
  • Figure 6.5 Leading Growth Hormone Drugs, Historical Sales Trend, Revenue ($m), 2011-2016
  • Figure 6.6 Global Growth Hormone Innovator Drugs Market, Market Share by Individual Drug (%), 2016
  • Figure 6.7 Global Growth Hormone Innovator Drugs Market Forecast, Market Share by Individual Drug (%), 2027
  • Figure 6.8 Norditropin Global Sales: Revenue ($million), 2011-2016
  • Figure 6.9 Norditropin Sales Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 6.10 Norditropin Sales by Geography: Market Share (%), 2016
  • Figure 6.11 Genotropin Global Sales: Revenue ($million), AGR (%), 2011-2016
  • Figure 6.12 Genotropin Sales Forecast 2016-2027: Revenue ($million), AGR (%)
  • Figure 6.13 Genotropin Sales by Geography: Market Share (%), 2016
  • Figure 6.14 Humatrope Global Sales: Revenue ($million), AGR (%), 2011-2016
  • Figure 6.15 Humatrope Sales Forecast 2016-2027: Revenue ($million), AGR (%)
  • Figure 6.16 Humatrope Sales by Geography: Market Share (%), 2016
  • Figure 6.17 Saizen Global Sales: Revenue ($million), AGR (%), 2011-2016
  • Figure 6.18 Saizen Sales Forecast 2016-2027: Revenue ($million), AGR (%)
  • Figure 6.19 Saizen Sales by Geography: Market Share (%), 2016
  • Figure 6.20 Nutropin and Nutropin AQ Combined Global Sales: Revenue ($million), 2011-2016
  • Figure 6.21 Nutropin and Nutropin AQ Combined Sales Forecast 2016-2027: Revenue ($million), AGR (%)
  • Figure 6.22 Nutropin and Nutropin AQ Combined Sales by Geography: Market Share (%), 2016
  • Figure 6.23 Global Growth Hormone Biosimilars Market Share by Individual Drug (%), 2016
  • Figure 6.24 Global Growth Hormone Biosimilars Market Share by Individual Drug (%), 2027
  • Figure 6.25 Omnitrope Global Sales: Revenue ($million), AGR (%), CAGR (%) 2011-2016
  • Figure 6.26 Omnitrope Sales Forecast 2016-2027: Revenue ($million), AGR (%)
  • Figure 6.27 Omnitrope Sales by Geography: Market Share (%), 2016
  • Figure 7.1 Global Growth Hormone Drugs Market Segmentation by Region/Country
  • Figure 7.2 Global Growth Hormone Drugs Market by Region: Revenue ($m)
  • Figure 7.3 Global Growth Hormone Drugs Market by Region: Market Share 2016 (%)
  • Figure 7.4 Global Growth Hormone Drugs Market by Country: Revenue ($m)
  • Figure 7.5 Global Growth Hormone Drugs Market by Country: Market Share (%)
  • Figure 7.6 Global Growth Hormone Drugs Market Historical Revenue by Region: Revenue ($m), Global AGR (%), 2011-2016
  • Figure 7.7 Global Growth Hormone Drugs Market Historical Revenue by Region 2016, 2027: Revenue ($m), CAGR 2016-2027 (%)
  • Figure 7.8 Global Growth Hormone Drugs Market by Region: AGR (%) 2012-2016
  • Figure 7.9 Global Growth Hormone Drugs Market by Region: Historical Market Share 2011-2016 (%)
  • Figure 7.10 Global Growth Hormone Drugs Market Forecast by Region: Revenue ($m), Global AGR (%), 2016-2027
  • Figure 7.11 Global Growth Hormone Drugs Market by Region: AGR (%) 2016-2027
  • Figure 7.12 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2017-2027 (%)
  • Figure 7.13 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2017 (%)
  • Figure 7.14 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2021 (%)
  • Figure 7.15 Global Growth Hormone Drugs Market by Region: Market Share Forecast 2027 (%)
  • Figure 7.16 US Growth Hormone Drugs Market: 2016 Revenue ($m), Market Share (%)
  • Figure 7.17 US Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%)
  • Figure 7.18 US Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 7.19 EU5 Growth Hormone Drugs Market 2016: Global Market Share (%)
  • Figure 7.20 EU5 Growth Hormone Drugs Market Countries 2016: Market Share (%)
  • Figure 7.21 EU5 Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%)
  • Figure 7.22 EU5 Growth Hormone Drugs Market Forecast Countries 2016 and 2027: Revenue ($m), CAGR 2016-2027 (%)
  • Figure 7.23 EU5 Growth Hormone Drugs Market by Region: Historical Market Share Forecast 2011-2016 (%)
  • Figure 7.24 EU5 Growth Hormone Drugs Market Forecast: Global Market Share 2027(%)
  • Figure 7.25 EU5 Growth Hormone Drugs Market Forecast By Country 2016-2027: Revenue ($m), AGR (%)
  • Figure 7.26 EU5 Growth Hormone Drugs Market By Region: Market Share Forecast 2017-2027 (%)
  • Figure 7.27 EU5 Growth Hormone Drugs Market Forecast by Region: Global Market Share 2027(%)
  • Figure 7.28 EU5 Growth Hormone Drugs Market Forecast by Region: Market Share 2017(%)
  • Figure 7.29 EU5 Growth Hormone Drugs Market Forecast by Region: Market Share 2027 (%)
  • Figure 7.30 EU5 Global Growth Hormone Drugs Market Forecast by Region: AGR 2016-2027 (%)
  • Figure 7.31 UK Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%),2016-2027
  • Figure 7.32 Spain Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 7.33 Italy Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 7.34 Germany Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 7.35 France Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 7.36 Japan Growth Hormone Drugs Market Historical Sales 2011-2016: Revenue ($m), AGR (%)
  • Figure 7.37 Japan Growth Hormone Drugs Market Forecast: Revenue ($m), AGR (%), 2016-2027
  • Figure 8.1 Growth Hormone Drugs Clinical Trial Pipeline Segmentation by Phase, 2017
  • Figure 8.2 Key Late-stage Clinical Trials of VRS-317
  • Figure 9.1 Global Growth Hormone Drugs Market by Company: Revenue ($m)
  • Figure 10.1 Global Growth Hormone Drugs Market by Company: Revenue ($m)
  • Figure 10.2 Global Growth Hormone Drugs Market by Company 2016: Market Share (%)
  • Figure 10.3 Global Growth Hormone Drugs Market by Company 2011 and 2016: Revenue ($m)
  • Figure 10.4 Global Growth Hormone Drugs Market by Top 5 Companies 2011-2016: Revenue ($m), Global AGR (%)
  • Figure 10.5 Global Growth Hormone Drugs Market by Company Share 2011-2016
  • Figure 10.6 Global Growth Hormone Drugs Market by Company Share 2011-2016
  • Figure 11.1 Global Growth Hormone Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 11.2 Growth Hormone Drugs Clinical Trials Pipeline Segmentation by Phase, 2017

Companies Listed

  • Acsendis Pharma
  • Aeterna Zentaris
  • Alteogen
  • Altus Pharmaceuticals
  • Amgen
  • Biogenomics
  • Critical Pharmaceuticals
  • Eli Lilly and Co
  • European Medicines Agency (EMA)
  • Ferring Pharmaceuticals
  • Food and Drugs Administration (FDA)
  • FortuneRock
  • Genentech
  • GeneScience Pharmaceuticals
  • Genexine
  • Hanmi Pharmaceutical
  • Ipsen
  • JCR Pharmaceuticals
  • LG
  • Merck KGaA
  • Novartis
  • Novo Nordisk
  • Opko Health
  • Pfenex
  • Pfizer
  • Pharmacia and Upjohn
  • Roche
  • Roche
  • Sereno Laboratories
  • Somatropin BioPartners
  • Teva
  • Versatis
  • World Health Organisation (WHO)
  • National Institute for Health and Care Excellence (NICE)>
Back to Top